The US Supreme Court has refused a request from Teva to stay an appeals court order, meaning the pharmaceutical company will lose exclusivity on Copaxone in May next year, rather than in 2015.
Aaron Cooper, chief counsel for IP and antitrust law in the US Senate Judiciary Committee, is to join law firm Covington & Burling LLP.
US pharmaceutical company Forest Laboratories and drug company Actavis have settled a legal dispute over a patent protecting blood pressure drug Bystoli (nebivolol).
The UK Patents Court has referred four questions to the CJEU seeking clarification on how the SPC Regulation should be interpreted in relation to drug products made of a combination of active ingredients.
The Indian Patent Office has rejected an application for a compulsory licence that was filed by domestic drug maker BDR Pharmaceuticals.
Mr Justice Arnold has refused to recuse himself from a patent trial after he was accused of being conflicted by an expert witness.
Patent litigator Jonathan Radcliffe has left Mayer Brown to become partner at Charles Russell LLP.
Bayer has appealed against the IPAB’s compulsory licence order that allows domestic generic maker Natco Pharma to market its own version of liver and kidney cancer drug Nexavar, this time at the Mumbai High Court.
Teva Pharmaceutical Industries has claimed victory in a patent revocation action brought by generic drug maker Mylan in the Hague over its blockbuster Copaxone drug, used in the treatment of multiple sclerosis.
Mylan Inc will be forced to divest injectable generic drugs before it can complete a proposed $1.85 billion acquisition of Agila Specialities Global Pte Ltd and Agila Specialties Pvt Ltd after the FTC applied conditions to the deal.